Developer docs
API playgroundTry for free, no card

Search company profiles

Checkpoint Surgical

Full company profile

uuid00023k3

Namestring
Checkpoint Surgical
Legal namestring
Checkpoint Surgical, Inc.
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Checkpoint Surgical, Inc. is a Cleveland, Ohio–based (Independence, Ohio headquarters) privately held medical device company founded in 2009 that develops, manufactures, and sells products used by surgeons to locate, evaluate, and protect peripheral nerves during surgical procedures. The company is organized around a "nerve care" franchise spanning three product categories: intraoperative nerve stimulators (CHECKPOINT GUARDIAN Model 9095, CHECKPOINT GEMINI Model 9092, CHECKPOINT Model 9094, and CHECKPOINT HEAD & NECK Model 9394), surgical instruments (CHECKPOINT EDGE Nerve Cutting Kit Model 9250), and biomaterial implants (CHECKPOINT ACMShield dehydrated placental membrane allograft, NeuroShield chitosan membrane, ProVeil soft tissue barrier, and CHECKPOINT AxioCor flexible nerve conduit). All CHECKPOINT stimulators use the company's proprietary biphasic waveform technology, which the company advertises as safe for prolonged or repeated stimulation without diminished response.

The company generates revenue predominantly through direct hardware and biomaterial sales to hospitals and ambulatory surgical centers via a sales-led go-to-market motion staffed by clinical and technical representatives. Surgeons — including orthopedic, neurosurgical, and plastic/reconstructive specialists — are the primary clinical users, with the company also supporting referral pathways into emerging procedures such as Targeted Muscle Reinnervation (TMR) for post-amputation pain. Product adoption is supported by an investment in clinical education resources including a virtual lecture series, virtual course library, nerve manuals, surgeon interviews, and ongoing clinical trials (FASTR-TEN, PHINEST, BES Therapy, PHONES). The company has secured FDA 510(k) clearances for the GEMINI stimulator and NeuroShield chitosan membrane (K190246), ISO 13485:2016 certification, and a CE Mark for European market access.

Checkpoint Surgical has raised approximately $48.7 million across nine funding rounds since 2009, with a $16 million equity financing in August 2021 led by River Cities Capital (now RC Capital) alongside First Analysis, JumpStart Inc., and Mutual Capital Partners, and a $4 million exempt offering in mid-2024. In August 2021 the company also acquired NeuroShield to expand its biomaterial portfolio. Leadership is anchored by CEO Derek Lewis, Founder/Executive Advisor Leonard M. Cosentine, and CFO Laura Keck, with the company operating from a 51–100 person organization focused commercially on the United States and regulatory-ready for Europe through its CE Mark.

Short descriptiontext

Checkpoint Surgical is a Cleveland-based medical device company that develops and sells intraoperative nerve stimulators, biomaterial implants, and surgical instruments used by surgeons to locate, evaluate, and protect peripheral nerves during surgical procedures.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersIndependence, United States
HQ citystring
Independence
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nerve stimulation devices, peripheral nerve surgery, intraoperative surgical devices, surgical biomaterial allografts, nerve repair products
Industry4 codes
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAI
Neural & Spinal Cord Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAB
Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAKAIAM
Pain Medicine (Interventional/Neuropathic Pain)
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
SIC code3 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Peripheral Nerve Surgery Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Checkpoint Surgical generates revenue through the sale of medical devices including nerve stimulators, biomaterial implants, and specialized surgical instruments for peripheral nerve surgery.

checkpointsurgical.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1CHECKPOINT GUARDIAN
Description

Nerve Stimulator product line

checkpointsurgical.com
+3 more records
Core offering1 text field

Checkpoint Surgical manufactures and sells intraoperative nerve stimulation devices, biomaterial allografts, and specialized surgical instruments used by surgeons to locate, evaluate, and protect peripheral nerves during surgical procedures. The portfolio spans nerve stimulators (GUARDIAN, GEMINI, CHECKPOINT, HEAD & NECK), the EDGE nerve cutting kit, and biomaterial barriers (ACMShield placental membrane, NeuroShield chitosan membrane, ProVeil soft tissue barrier, AxioCor flexible nerve conduit) covering the nerve care pathway from identification through repair and healing.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Checkpoint Surgical is a medical device company offering a portfolio of intraoperative nerve stimulation devices, biomaterial implants, and specialized surgical instruments for peripheral nerve surgery. The product portfolio includes three main stimulator product lines: CHECKPOINT GUARDIAN (Model 9095) and CHECKPOINT GEMINI (Model 9092) for nerve stimulation, and the original CHECKPOINT (Model 9094) Nerve Stimulator/Locator. The company also provides specialized instruments like the CHECKPOINT EDGE Nerve Cutting Kit for surgical preparation, and biomaterial products including CHECKPOINT ACMShield (dehydrated placental membrane allograft), NeuroShield chitosan membrane, and ProVeil soft tissue barriers. All CHECKPOINT stimulators utilize biphasic waveform technology, described as safe for prolonged or repeated stimulation without diminished response.

Product and service1 record
1CHECKPOINT GUARDIAN (Model 9095)
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

MiMedx manufactures dehydrated amniotic membrane allografts (e.g., EpiFix, AmnioFix) used as surgical barriers and wound coverings — directly overlapping with Checkpoint's ACMShield dehydrated placental membrane allograft in surgical soft tissue barrier applications.

TypeBroad incumbent
Description

Stryker is a large orthopedic and surgical instruments incumbent whose extremities and sports medicine franchises overlap with Checkpoint's orthopedic nerve surgery customer base, and could expand into nerve-specific instruments over time.

TypeBroad incumbent
Description

Medtronic is a dominant incumbent in implantable neurostimulation (spinal cord, deep brain, peripheral nerve stimulation systems) and neuromonitoring, providing the broad competitive backdrop against which Checkpoint's intraoperative peripheral nerve stimulators compete for surgeon mindshare and OR shelf space.

TypeDirect peer
Description

AxoGen is the leading pure-play peripheral nerve repair company, offering nerve grafts, connectors, and caps — directly overlapping with Checkpoint's nerve repair and conduit (AxioCor) portfolio across the same surgical customer base of plastic, orthopedic, and reconstructive surgeons.

TypeBroad incumbent
Description

Boston Scientific operates a sizable neuromodulation franchise (Precision, Spectra, Vercise) and competes for peripheral nerve stimulation budgets; its scale and existing hospital contracts make it a key competitor for Checkpoint's intraoperative nerve stimulation accounts.

TypeBroad incumbent
Description

Natus Medical supplies neurology-focused diagnostic and monitoring equipment used in surgical and clinical nerve assessment, an adjacent competitor for intraoperative nerve monitoring budgets that hospitals allocate alongside stimulators.

TypeEmerging player
Description

Polyganics develops bioresorbable nerve repair devices (Neurolac nerve guides) and other tissue regeneration products — a smaller European peer competing in nerve conduits and repair scaffolds similar to Checkpoint's AxioCor and ACMShield.

TypeEmerging player
Description

Synapse Biomedical develops neurostimulation devices (including the NeuRx diaphragm pacing system) and EMG-based surgical products — a smaller peer with overlap on intraoperative nerve stimulation and EMG-driven surgical decision-making.

TypeDirect peer
Description

Integra offers nerve repair products (NeuraGen nerve guides, NeuraWrap) and regenerative tissue technologies that compete directly with Checkpoint's AxioCor conduit and ACMShield biomaterial lines, serving the same peripheral nerve surgery market.

TypeBroad incumbent
Description

Abbott's neuromodulation business (Proclaim DRG, BurstDR, Prodigy) targets dorsal root ganglion and spinal cord stimulation, adjacent to peripheral nerve applications and competing for the same neurology and pain-medicine procedure budgets as Checkpoint.

Market position
Competitive moat4 records

Each record includes

Type, Details

Key highlights1 record

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Checkpoint Surgical

Peripheral Nerve Surgery Devicescheckpointsurgical.com

Checkpoint Surgical is a Cleveland-based medical device company that develops and sells intraoperative nerve stimulators, biomaterial implants, and surgical instruments used by surgeons to locate, evaluate, and protect peripheral nerves during surgical procedures.

What Checkpoint Surgical does

Checkpoint Surgical, Inc. is a Cleveland, Ohio–based (Independence, Ohio headquarters) privately held medical device company founded in 2009 that develops, manufactures, and sells products used by surgeons to locate, evaluate, and protect peripheral nerves during surgical procedures. The company is organized around a "nerve care" franchise spanning three product categories: intraoperative nerve stimulators (CHECKPOINT GUARDIAN Model 9095, CHECKPOINT GEMINI Model 9092, CHECKPOINT Model 9094, and CHECKPOINT HEAD & NECK Model 9394), surgical instruments (CHECKPOINT EDGE Nerve Cutting Kit Model 9250), and biomaterial implants (CHECKPOINT ACMShield dehydrated placental membrane allograft, NeuroShield chitosan membrane, ProVeil soft tissue barrier, and CHECKPOINT AxioCor flexible nerve conduit). All CHECKPOINT stimulators use the company's proprietary biphasic waveform technology, which the company advertises as safe for prolonged or repeated stimulation without diminished response.

The company generates revenue predominantly through direct hardware and biomaterial sales to hospitals and ambulatory surgical centers via a sales-led go-to-market motion staffed by clinical and technical representatives. Surgeons — including orthopedic, neurosurgical, and plastic/reconstructive specialists — are the primary clinical users, with the company also supporting referral pathways into emerging procedures such as Targeted Muscle Reinnervation (TMR) for post-amputation pain. Product adoption is supported by an investment in clinical education resources including a virtual lecture series, virtual course library, nerve manuals, surgeon interviews, and ongoing clinical trials (FASTR-TEN, PHINEST, BES Therapy, PHONES). The company has secured FDA 510(k) clearances for the GEMINI stimulator and NeuroShield chitosan membrane (K190246), ISO 13485:2016 certification, and a CE Mark for European market access.

Checkpoint Surgical has raised approximately $48.7 million across nine funding rounds since 2009, with a $16 million equity financing in August 2021 led by River Cities Capital (now RC Capital) alongside First Analysis, JumpStart Inc., and Mutual Capital Partners, and a $4 million exempt offering in mid-2024. In August 2021 the company also acquired NeuroShield to expand its biomaterial portfolio. Leadership is anchored by CEO Derek Lewis, Founder/Executive Advisor Leonard M. Cosentine, and CFO Laura Keck, with the company operating from a 51–100 person organization focused commercially on the United States and regulatory-ready for Europe through its CE Mark.

Checkpoint Surgical firmographics

Firmographics
Name
Checkpoint Surgical
Legal name
Checkpoint Surgical, Inc.
Website
https://checkpointsurgical.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
51–100 employees
Short description
Checkpoint Surgical is a Cleveland-based medical device company that develops and sells intraoperative nerve stimulators, biomaterial implants, and surgical instruments used by surgeons to locate, evaluate, and protect peripheral nerves during surgical procedures.
Ownership category
akta.pro rank

Checkpoint Surgical industry classification

Industry
Product category
Peripheral Nerve Surgery Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAI
Neural & Spinal Cord Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAB
Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAKAIAM
Pain Medicine (Interventional/Neuropathic Pain)

Keywords

  • Nerve stimulation devices
  • Peripheral nerve surgery
  • Intraoperative surgical devices
  • Surgical biomaterial allografts
  • Nerve repair products

Where Checkpoint Surgical is headquartered

Location

Headquarters

HQ city
Independence
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Checkpoint Surgical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales: Checkpoint Surgical generates revenue through the sale of medical devices including nerve stimulators, biomaterial implants, and specialized surgical instruments for peripheral nerve surgery.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Checkpoint Surgical product offering

Product offering

Core offering

Checkpoint Surgical manufactures and sells intraoperative nerve stimulation devices, biomaterial allografts, and specialized surgical instruments used by surgeons to locate, evaluate, and protect peripheral nerves during surgical procedures. The portfolio spans nerve stimulators (GUARDIAN, GEMINI, CHECKPOINT, HEAD & NECK), the EDGE nerve cutting kit, and biomaterial barriers (ACMShield placental membrane, NeuroShield chitosan membrane, ProVeil soft tissue barrier, AxioCor flexible nerve conduit) covering the nerve care pathway from identification through repair and healing.

Product overview

Checkpoint Surgical is a medical device company offering a portfolio of intraoperative nerve stimulation devices, biomaterial implants, and specialized surgical instruments for peripheral nerve surgery. The product portfolio includes three main stimulator product lines: CHECKPOINT GUARDIAN (Model 9095) and CHECKPOINT GEMINI (Model 9092) for nerve stimulation, and the original CHECKPOINT (Model 9094) Nerve Stimulator/Locator. The company also provides specialized instruments like the CHECKPOINT EDGE Nerve Cutting Kit for surgical preparation, and biomaterial products including CHECKPOINT ACMShield (dehydrated placental membrane allograft), NeuroShield chitosan membrane, and ProVeil soft tissue barriers. All CHECKPOINT stimulators utilize biphasic waveform technology, described as safe for prolonged or repeated stimulation without diminished response.

Differentiator

Problem solved

Functional benefit

Brands

  • CHECKPOINT GUARDIAN: Nerve Stimulator product line
  • CHECKPOINT GEMINI
  • CHECKPOINT ACMShield
  • CHECKPOINT EDGE

Products and services

  • CHECKPOINT GUARDIAN (Model 9095)

Companies that use Checkpoint Surgical

Customer profile

Segments2 records

Ideal customer profiles2 records

Checkpoint Surgical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Checkpoint Surgical partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Checkpoint Surgical competitors and assessment

Company assessment

Direct peers

  • MiMedx: MiMedx manufactures dehydrated amniotic membrane allografts (e.g., EpiFix, AmnioFix) used as surgical barriers and wound coverings — directly overlapping with Checkpoint's ACMShield dehydrated placental membrane allograft in surgical soft tissue barrier applications.
  • AxoGen: AxoGen is the leading pure-play peripheral nerve repair company, offering nerve grafts, connectors, and caps — directly overlapping with Checkpoint's nerve repair and conduit (AxioCor) portfolio across the same surgical customer base of plastic, orthopedic, and reconstructive surgeons.
  • Integra LifeSciences: Integra offers nerve repair products (NeuraGen nerve guides, NeuraWrap) and regenerative tissue technologies that compete directly with Checkpoint's AxioCor conduit and ACMShield biomaterial lines, serving the same peripheral nerve surgery market.

Broad incumbents

  • Stryker: Stryker is a large orthopedic and surgical instruments incumbent whose extremities and sports medicine franchises overlap with Checkpoint's orthopedic nerve surgery customer base, and could expand into nerve-specific instruments over time.
  • Medtronic: Medtronic is a dominant incumbent in implantable neurostimulation (spinal cord, deep brain, peripheral nerve stimulation systems) and neuromonitoring, providing the broad competitive backdrop against which Checkpoint's intraoperative peripheral nerve stimulators compete for surgeon mindshare and OR shelf space.
  • Boston Scientific: Boston Scientific operates a sizable neuromodulation franchise (Precision, Spectra, Vercise) and competes for peripheral nerve stimulation budgets; its scale and existing hospital contracts make it a key competitor for Checkpoint's intraoperative nerve stimulation accounts.
  • Natus Medical: Natus Medical supplies neurology-focused diagnostic and monitoring equipment used in surgical and clinical nerve assessment, an adjacent competitor for intraoperative nerve monitoring budgets that hospitals allocate alongside stimulators.
  • Abbott (Neuromodulation): Abbott's neuromodulation business (Proclaim DRG, BurstDR, Prodigy) targets dorsal root ganglion and spinal cord stimulation, adjacent to peripheral nerve applications and competing for the same neurology and pain-medicine procedure budgets as Checkpoint.

Emerging players

  • Polyganics: Polyganics develops bioresorbable nerve repair devices (Neurolac nerve guides) and other tissue regeneration products — a smaller European peer competing in nerve conduits and repair scaffolds similar to Checkpoint's AxioCor and ACMShield.
  • Synapse Biomedical: Synapse Biomedical develops neurostimulation devices (including the NeuRx diaphragm pacing system) and EMG-based surgical products — a smaller peer with overlap on intraoperative nerve stimulation and EMG-driven surgical decision-making.

Market position

Competitive moat4 records

Key highlights1 record

Customer concentration

Checkpoint Surgical social profiles

Digital presence

Checkpoint Surgical compliance and trust

Trust signal

Compliance3 records

Checkpoint Surgical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Checkpoint Surgical leadership team

Management profile

Number of profiles

Profiles3 records

Checkpoint Surgical funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Checkpoint Surgical M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Checkpoint Surgical

What does Checkpoint Surgical do?

Checkpoint Surgical manufactures and sells intraoperative nerve stimulation devices, biomaterial allografts, and specialized surgical instruments used by surgeons to locate, evaluate, and protect peripheral nerves during surgical procedures. The portfolio spans nerve stimulators (GUARDIAN, GEMINI, CHECKPOINT, HEAD & NECK), the EDGE nerve cutting kit, and biomaterial barriers (ACMShield placental membrane, NeuroShield chitosan membrane, ProVeil soft tissue barrier, AxioCor flexible nerve conduit) covering the nerve care pathway from identification through repair and healing.

Is Checkpoint Surgical a public or private company?

Checkpoint Surgical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Checkpoint Surgical founded?

Checkpoint Surgical was founded in 2010. It employs 51 to 100 people.

Where is Checkpoint Surgical based?

Checkpoint Surgical is headquartered in Independence, United States, in the North America region.

How does Checkpoint Surgical make money?

One revenue line is on record: medical Device Sales.

Who are Checkpoint Surgical's main competitors?

Direct peers on record are MiMedx, AxoGen and Integra LifeSciences. Broad incumbents are Stryker, Medtronic, Boston Scientific, Natus Medical and Abbott (Neuromodulation). Emerging players are Polyganics and Synapse Biomedical.

Does Checkpoint Surgical have an API?

No public API is recorded for Checkpoint Surgical.

What industry is Checkpoint Surgical in?

Checkpoint Surgical's product category is Peripheral Nerve Surgery Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAAAGAI, Neural & Spinal Cord Regeneration. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SecSEC FORM DThe Securities and Exchange Commission (SEC) has received a new filing from Checkpoint Surgical, Inc. for the offering of securities under Regulation D. The total offering amount is $4,000,000 with 42 investors already participating, and the offering will not last more than one year.PR NewswireCheckpoint Surgical announces organizational changes to support the company's rapid growth in the nerve care market spaceCheckpoint Surgical promoted Derek Lewis to President and CEO, with Len Cosentino transitioning to Founder and Executive Advisor. The company also added a Chief Commercial Officer and promoted several other executives. Checkpoint expects to launch the Checkpoint Gemini Bipolar Stimulator in September 2022.PR NewswireCheckpoint Surgical Enrolls First Patient in Nerve Regeneration Clinical StudyCheckpoint Surgical, Inc. announced the enrollment of the first patient in its multi-center clinical study evaluating the company's nerve regeneration technology at The Ohio State University. The double-blind, randomized trial will test the FDA Breakthrough Device-designated BEST (Brief Electrical Stimulation Therapy) system across four sites including Ohio State, Northwestern, Medical College of Wisconsin, and Walter Reed, with funding from a Department of Defense Clinical Trial Award. The system is designed to provide electrical stimulation to promote nerve regeneration as an adjunct to surgical intervention following peripheral nerve injury.BioSpaceCheckpoint Surgical Completes $16M Equity Financing to Fuel Growth and Launch New ProductsCheckpoint Surgical completed a $16 million equity financing round led by River Cities Capital to support sales expansion and new product launches. The company plans to utilize the funds for research and development, including its recently acquired NeuroShield nerve wrap technology. This capital raise aims to accelerate growth in the peripheral nerve care sector.CheckpointsurgicalCheckpoint Surgical Completes $16M Equity Financing to Fuel Growth and Launch New ProductsCheckpoint Surgical completed a $16 million equity financing round led by River Cities Capital to support sales expansion and new product launches. The funding also included participation from existing backers such as Mutual Capital Partners, JumpStart NEXT Fund, and First Analysis. Checkpoint plans to utilize the capital for growing its specialized sales force and advancing research and development in peripheral nerve care.FinSMEsCheckpoint Surgical Raises $16M in Equity FundingCheckpoint Surgical, Inc. raised $16 million in equity funding led by River Cities Capital with participation from Mutual Capital Partners, JumpStart NEXT Fund, and First Analysis. The company plans to utilize the capital for sales force expansion, research and development, and the launch of new products including the NeuroShield nerve wrap.startupticker.chMonarch BioImplants’ assets acquired by US companyCheckpoint Surgical Inc., a privately held medical device company based in Cleveland, Ohio, acquired NeuroShield Chitosan Nerve Wrap technology from Swiss biomedical startup Monarch BioImplants GmbH in March 2021, marking Checkpoint's first chitosan-based biological implant product. Monarch's founders Thomas Freier and Rivelino Montenegro joined the Checkpoint team as part of the deal, bringing expertise in chitosan technology to support the company's expansion into peripheral nerve repair. The NeuroShield implant, which gained international market access through a €20 million investment from GEM Global Yield LLC SCS, is FDA-cleared and currently available in the United States, Israel, and South Africa.SecSEC FORM DCheckpoint Surgical, Inc. filed a Form D with the SEC for an exempt offering of equity securities under Rule 506(b). The company disclosed a total offering amount of $16 million USD, with approximately $13 million already sold to six investors as of late May 2021. This regulatory filing confirms the ongoing capital raise for the Ohio-based medical device company.PR NewswireCheckpoint Surgical Named by Crain's Cleveland Business as One of Ohio's Best Employers in 2020Crain's Cleveland Business named Checkpoint Surgical one of the 2020 Best Employers in Ohio as part of a statewide survey and awards program recognizing best places of employment. The two-part evaluation process weighted workplace policies at 25% and employee survey responses at 75%, with 42 companies making the final list. Checkpoint Surgical President and CEO Len Cosentino expressed pride in the recognition, particularly during challenging times.